Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 26-50 of 57 citing articles:

Targeting the epigenetic reader “BET” as a therapeutic strategy for cancer
Abhishek Wahi, Namish Manchanda, Priti Jain, et al.
Bioorganic Chemistry (2023) Vol. 140, pp. 106833-106833
Closed Access | Times Cited: 7
Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis
Xuetao Chen, Tingting Wu, Zhiyan Du, et al.
European Journal of Medicinal Chemistry (2023) Vol. 265, pp. 116080-116080
Closed Access | Times Cited: 7
Suppression of lysosome metabolism-meditated GARP/TGF-β1 complexes specifically depletes regulatory T cells to inhibit breast cancer metastasis
Jing Ma, Yutong Chen, Tao Li, et al.
Oncogene (2024) Vol. 43, Iss. 25, pp. 1930-1940
Open Access | Times Cited: 2
BRD4 promotes gouty arthritis through MDM2-mediated PPARγ degradation and pyroptosis
Xiaoxia Xu, Hongbin Qiu
Molecular Medicine (2024) Vol. 30, Iss. 1
Open Access | Times Cited: 2
Improved methods for targeting epigenetic reader domains of acetylated and methylated lysine
Isabelle A. Engelberg, Caroline A. Foley, Lindsey I. James, et al.
Current Opinion in Chemical Biology (2021) Vol. 63, pp. 132-144
Open Access | Times Cited: 17
Progress in the development of domain selective inhibitors of the bromo and extra terminal domain family (BET) proteins
Yuantao Fu, Yanzhi Zhang, Haiying Sun
European Journal of Medicinal Chemistry (2021) Vol. 226, pp. 113853-113853
Closed Access | Times Cited: 17
LncRNA HOTTIP promotes inflammatory response in acute gouty arthritis via miR‐101‐3p/BRD4 axis
Ping Shao, Huijie Liu, Yan-Yan Xue, et al.
International Journal of Rheumatic Diseases (2022) Vol. 26, Iss. 2, pp. 305-315
Closed Access | Times Cited: 11
Discovery of Benzo[d]imidazole‐6‐sulfonamides as Bromodomain and Extra‐Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain
Alessandra Cipriano, Ciro Milite, Alessandra Feoli, et al.
ChemMedChem (2022) Vol. 17, Iss. 20
Open Access | Times Cited: 10
Discovery of 1-(5-(1H-benzo[d]imidazole-2-yl)-2,4-dimethyl-1H-pyrrol-3-yl)ethan-1-one derivatives as novel and potent bromodomain and extra-terminal (BET) inhibitors with anticancer efficacy
Bo Kong, Zhaohong Zhu, Hongmei Li, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113953-113953
Closed Access | Times Cited: 13
Domain-Selective BET Ligands Yield Next-Generation Synthetic Genome Readers/Regulators with Nonidentical Cellular Functions
Mohammed Ashraf, M. Brett Waddell, Ieva Sutkevičiu̅tė, et al.
Journal of the American Chemical Society (2023)
Closed Access | Times Cited: 5
Discovery of (R)-4-(8-methoxy-2-methyl-1-(1-phenylethy)-1H-imidazo[4,5-c]quinnolin-7-yl)-3,5-dimethylisoxazole as a potent and selective BET inhibitor for treatment of acute myeloid leukemia (AML) guided by FEP calculation
Su Yu, Yan Zhang, Jie Yang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 263, pp. 115924-115924
Closed Access | Times Cited: 5
Systemic Investigation of Promoter-wide Methylome and Genome Variations in Gout
Chia‐Chun Tseng, Man Chun Wong, Wei‐Ting Liao, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 13, pp. 4702-4702
Open Access | Times Cited: 13
Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis
Xuetao Chen, Fanying Meng, Jingtian Zhang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114423-114423
Closed Access | Times Cited: 8
Targeting bromodomian-containing protein 8 (BRD8): An advanced tool to interrogate BRD8
Tingting Wu, Yali Chen, Qidong You, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116271-116271
Closed Access | Times Cited: 1
Insights into the eradication of drug resistant Staphylococcus aureus via compound 6-nitrobenzo[cd]indole-2(1H)-ketone
Hongshuang Qin, Lin Li, Shuhan Chen, et al.
Journal of Materials Chemistry B (2024) Vol. 12, Iss. 10, pp. 2481-2485
Closed Access | Times Cited: 1
Discovery of indole-2-one derivatives as BRD4 (BD1) selective inhibitors
Xue-Peng Qiao, Xueting Wang, Shuai Wang, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 106, pp. 117752-117752
Closed Access | Times Cited: 1
A Review of the Bromodomain and Extraterminal Domain Epigenetic Reader Proteins: Function on Virus Infection and Cancer
Mengli Wu, Guiquan Guan, Hong Yin, et al.
Viruses (2024) Vol. 16, Iss. 7, pp. 1096-1096
Open Access | Times Cited: 1
Design, synthesis and biological evaluation of novel 6-phenyl-1,3a,4,10b-tetrahydro-2H-benzo[c]thiazolo[4,5-e]azepin-2-one derivatives as potential BRD4 inhibitors
Qifei Li, Jieming Li, Yan Cai, et al.
Bioorganic & Medicinal Chemistry (2020) Vol. 28, Iss. 15, pp. 115601-115601
Closed Access | Times Cited: 11
A positron emission tomography imaging probe selectively targeting the BD1 bromodomain and extra-terminal domain
Ping Bai, Yan Liu, Frederick A. Bagdasarian, et al.
Chemical Communications (2022) Vol. 58, Iss. 69, pp. 9654-9657
Open Access | Times Cited: 7
Design, synthesis, and biological evaluation of quinoxalinone derivatives as potent BRD4 inhibitors
Kai-Yan Xu, Xueting Wang, Lei Cheng, et al.
Bioorganic & Medicinal Chemistry (2022) Vol. 78, pp. 117152-117152
Closed Access | Times Cited: 7
Structural variation of protein–ligand complexes of the first bromodomain of BRD4
Ellen E. Guest, Stephen D. Pickett, Jonathan D. Hirst
Organic & Biomolecular Chemistry (2021) Vol. 19, Iss. 25, pp. 5632-5641
Open Access | Times Cited: 7
Design, synthesis and pharmacological characterization of N-(3-ethylbenzo[d]isoxazol-5-yl) sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia
Maofeng Zhang, Xiaoyu Luo, Cheng Zhang, et al.
Acta Pharmacologica Sinica (2022) Vol. 43, Iss. 10, pp. 2735-2748
Open Access | Times Cited: 3
Identification of highly efficacious PROTACs targeting BRD4 against acute myeloid leukemia: Design, synthesis, and biological evaluations
Aiping Chen, Yue Zhong, Yunxiao Liu, et al.
Chinese Chemical Letters (2022) Vol. 34, Iss. 6, pp. 107923-107923
Closed Access | Times Cited: 3
Marine natural product-inspired discovery of novel BRD4 inhibitors with anti-inflammatory activity
Shuxia Chen, Jichen Yang, Xiangyu Wang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 284, pp. 117193-117193
Closed Access
Discovery and optimization of novel 4-morpholinothieno[3,2-d]pyrimidine derivatives as potent BET inhibitors for cancer therapy
Kai Ran, Yong Li, Yimei Zhang, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107929-107929
Closed Access

Scroll to top